Literature DB >> 24573556

Ubiquitin-like with PHD and ring finger domains 2 is a predictor of survival and a potential therapeutic target in colon cancer.

Su Lu1, Dongwang Yan2, Zehua Wu2, Tao Jiang2, Jian Chen2, Lin Yuan1, Jun Lin1, Zhihai Peng2, Huamei Tang1.   

Abstract

In the present study, we investigated the expression of ubiquitin-like with PHD and ring finger domains 2 (UHRF2) in colon cancer and adjacent normal tissues and estimated the clinicopathological significance and predictive value of UHRF2 expression in colon cancer. Using quantitative real-time PCR, tissue microarray (TMA), western blot analysis and immunohistochemical staining, we evaluated UHRF2 mRNA and protein levels in tumor tissues and paired adjacent normal epithelium. We found that UHRF2 was upregulated at both the transcriptional and translational levels in tumor tissues. Immunohistochemical detection of UHRF2 on a TMA containing 203 paired specimens showed that increased cytoplasmic UHRF2 was significantly associated with clinical stage, depth of invasion, nodal involvement, tumor histologic grade and the presence of metastasis. Patients with UHRF2-positive tumors had a much lower disease-free survival [hazard ratio (HR) 9.511, P<0.001] and overall survival (HR 9.820, P<0.001). Univariate and multivariate analyses were performed to determine the correlation between these parameters and the clinical and pathological variables of the study population verifying that UHRF2 immunoreactivity emerged as an independent prognostic factor in the multivariate analysis. UHRF2 may contribute to the progression of colon carcinogenesis and function as a novel prognostic indicator after curative operation.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24573556     DOI: 10.3892/or.2014.3035

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  12 in total

1.  HBx promotes hepatocarcinogenesis by enhancing phosphorylation and blocking ubiquitinylation of UHRF2.

Authors:  Fengjuan Cheng; Guanhua Qian; Xianyun Fang; Jingjie Sun; Siyuan Chen; Rongjuan Chen; Shangjing Liu; Zhaodi Li; Kejia Wu; Shiming Jiang; Yong Chen; Ni Tang; Juan Chen; Changzhu Duan
Journal:  Hepatol Int       Date:  2021-04-19       Impact factor: 6.047

Review 2.  Ubiquitin proteasome system research in gastrointestinal cancer.

Authors:  Jia-Ling Zhong; Chang-Zhi Huang
Journal:  World J Gastrointest Oncol       Date:  2016-02-15

Review 3.  Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials.

Authors:  Yuan Cheng; Cai He; Manni Wang; Xuelei Ma; Fei Mo; Shengyong Yang; Junhong Han; Xiawei Wei
Journal:  Signal Transduct Target Ther       Date:  2019-12-17

4.  Multidimensional Proteomics Reveals a Role of UHRF2 in the Regulation of Epithelial-Mesenchymal Transition (EMT).

Authors:  Mi Lai; Lizhu Liang; Jiwei Chen; Naiqi Qiu; Sai Ge; Shuhui Ji; Tieliu Shi; Bei Zhen; Mingwei Liu; Chen Ding; Yi Wang; Jun Qin
Journal:  Mol Cell Proteomics       Date:  2016-04-25       Impact factor: 5.911

Review 5.  Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials.

Authors:  Yuan Cheng; Cai He; Manni Wang; Xuelei Ma; Fei Mo; Shengyong Yang; Junhong Han; Xiawei Wei
Journal:  Signal Transduct Target Ther       Date:  2019-12-17

6.  UHRF2 promotes Hepatocellular Carcinoma Progression by Upregulating ErbB3/Ras/Raf Signaling Pathway.

Authors:  Jingjie Sun; Kejia Wu; Siyuan Chen; Shiming Jiang; Yong Chen; Changzhu Duan
Journal:  Int J Med Sci       Date:  2021-06-26       Impact factor: 3.738

7.  Ampullary Cancers Harbor ELF3 Tumor Suppressor Gene Mutations and Exhibit Frequent WNT Dysregulation.

Authors:  Marie-Claude Gingras; Kyle R Covington; David K Chang; Lawrence A Donehower; Anthony J Gill; Michael M Ittmann; Chad J Creighton; Amber L Johns; Eve Shinbrot; Ninad Dewal; William E Fisher; Christian Pilarsky; Robert Grützmann; Michael J Overman; Nigel B Jamieson; George Van Buren; Jennifer Drummond; Kimberly Walker; Oliver A Hampton; Liu Xi; Donna M Muzny; Harsha Doddapaneni; Sandra L Lee; Michelle Bellair; Jianhong Hu; Yi Han; Huyen H Dinh; Mike Dahdouli; Jaswinder S Samra; Peter Bailey; Nicola Waddell; John V Pearson; Ivon Harliwong; Huamin Wang; Daniela Aust; Karin A Oien; Ralph H Hruban; Sally E Hodges; Amy McElhany; Charupong Saengboonmee; Fraser R Duthie; Sean M Grimmond; Andrew V Biankin; David A Wheeler; Richard A Gibbs
Journal:  Cell Rep       Date:  2016-01-21       Impact factor: 9.423

Review 8.  DNA methylation, its mediators and genome integrity.

Authors:  Huan Meng; Ying Cao; Jinzhong Qin; Xiaoyu Song; Qing Zhang; Yun Shi; Liu Cao
Journal:  Int J Biol Sci       Date:  2015-04-08       Impact factor: 6.580

9.  UHRF2 decreases H3K9ac expression by interacting with it through the PHD and SRA/YDG domain in HepG2 hepatocellular carcinoma cells.

Authors:  Ting Zhang; Linglin Zhao; Shengyuan Zeng; Lu Bai; Junxia Chen; Zheng Zhang; Yalan Wang; Changzhu Duan
Journal:  Int J Mol Med       Date:  2016-11-17       Impact factor: 4.101

10.  Loss of UHRF2 expression is associated with human neoplasia, promoter hypermethylation, decreased 5-hydroxymethylcytosine, and high proliferative activity.

Authors:  Huarui Lu; Sweta Bhoopatiraju; Hongbo Wang; Nolan P Schmitz; Xiaohong Wang; Matthew J Freeman; Colleen L Forster; Michael R Verneris; Michael A Linden; Timothy C Hallstrom
Journal:  Oncotarget       Date:  2016-11-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.